°øÁö : µµÄìÁõ±Ç°Å·¡¼Ò JASDAQ ½ºÅÄ´Ùµå ½ÃÀå ½Å±Ô »óÀå °ü·Ã ¾È³»

Global Information
ȸ»ç¼Ò°³ | ¹®ÀÇ | ºñ±³¸®½ºÆ®

¼¼°èÀÇ °æ±¸ °íÇüÁ¦Á¦¿ë ºÎÇüÁ¦ ½ÃÀå : ¿¹Ãø(-2025³â)

Analysis of the Global Oral Solid Dosage Excipients Market, Forecast to 2025

¸®¼­Ä¡»ç Frost & Sullivan
¹ßÇàÀÏ 2020³â 06¿ù »óǰ ÄÚµå 943723
ÆäÀÌÁö Á¤º¸ ¿µ¹® 110 Pages
°¡°Ý
US $ 4,950 £Ü 5,477,000 Web Access (Regional License) help
¸®¼­Ä¡»çÀÇ À¥»çÀÌÆ®¿¡ ·Î±×ÀÎÇÒ ¼ö ÀÖ´Â ÆÐ½º¿öµå°¡ ¹ß±ÞµÇ¸ç, PDF¸¦ ´Ù¿î·Îµå ¹Þ´Â ÇüÅ·ΠÁ¦°øµË´Ï´Ù. µ¿ÀÏ ±¹°¡ ³»¿¡ ÀÖ´Â »ç¾÷ÀåÀÇ ¸ðµç ºÐµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, ÀÌ¿ë Àοø¼ö Á¦ÇÑÀº ¾ø½À´Ï´Ù. ÅØ½ºÆ® µîÀÇ PDF ³»¿ë ÆíÁýÀº ºÒ°¡´ÉÇÕ´Ï´Ù. ÀμâȽ¼ö¿¡ Á¦ÇÑÀº ¾øÀ¸³ª, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿¡ ÁØÇÕ´Ï´Ù.


¼¼°èÀÇ °æ±¸ °íÇüÁ¦Á¦¿ë ºÎÇüÁ¦ ½ÃÀå : ¿¹Ãø(-2025³â) Analysis of the Global Oral Solid Dosage Excipients Market, Forecast to 2025
¹ßÇàÀÏ : 2020³â 06¿ù ÆäÀÌÁö Á¤º¸ : ¿µ¹® 110 Pages

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹®¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹®¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ºÎÇüÁ¦´Â ¿ø·áÀǾàǰ(API) ¾ÈÁ¤¼º Çâ»ó, ¾à¹° ¹æÃâ Á¶Àý, ¹Ì°¢ °³¼± µî ´Ù¾çÇÑ ±â´ÉÀ» ´ã´çÇÏ´Â °ÍÀ¸·Î, °¢Á¾ ÀǾàǰ¿¡ ÀûÀýÇÑ ºÎÇüÁ¦ÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ºÎÇüÁ¦¿¡´Â ¾àÈ¿´Â ¾øÁö¸¸ API º¸È£³ª Á¦Á¶ °øÁ¤ °£¼ÒÈ­ µî Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇϰí ÀÖÀ¸¸ç, ºí·Ï¹ö½ºÅÍ ÀǾàǰÀÇ Æ¯Çã ±âÇÑ Á¾·á¿¡ µû¸¥ Á¦³×¸¯ ÀǾàǰ ¼ö¿ä È®´ë¿Í °¢ ȯÀÚ¿¡°Ô ÀûÇÕÇÑ ÀǾàǰ ¼ö¿ä È®´ë µîÀÇ ¿äÀÎÀÌ ¿øµ¿·ÂÀÌ µÇ¾î ½ÃÀåÀº ÇâÈÄ¿¡µµ ²ÙÁØÈ÷ ¼ºÀåÇÒ °ÍÀ¸·Î »ý°¢µË´Ï´Ù.

¼¼°èÀÇ °æ±¸ °íÇüÁ¦Á¦¿ë ºÎÇüÁ¦(Oral Solid Dosage Excipients) ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, ¾à»ç ±ÔÁ¦ °¡À̵å¶óÀÎ, ¼ºÀå ÃËÁø¿äÀΰú ÀúÇØ¿äÀÎ, µ¿Çâ°ú °æÀï »óȲ ºÐ¼®, ¼ºÀå ±âȸ, °¢ Áö¿ª ½ÃÀå ºÐ¼® µîÀÇ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ¿ä¾à - Àü·«Àû ÆÑÆ®½ÃÆ®
  • ½ÃÀå ¿£Áö´Ï¾î¸µ ÃøÁ¤
  • CEOÀÇ °ßÇØ

½ÃÀå °³¿ä

  • ½ÃÀå Á¤ÀÇ
  • ½ÃÀå ¼¼ºÐÈ­
  • Áö¿ªÀû ¹üÀ§
  • º» Á¶»ç¿¡¼­ ´ëÀÀÇÏ´Â ÁÖ¿ä Àǹ®Á¡
  • Áö¿ªº° ¸ÅÃâ ¿¹Ãø
  • ½ÃÀå ¼¼ºÐÈ­ ÇØ¼³

¾à»ç ±ÔÁ¦ °¡À̵å¶óÀÎ

  • ºÎÇüÁ¦¿Í °³¿ä¼­
  • GMP °¡À̵å ŸÀÓ¶óÀÎ
  • ÀÎÁõ Çʿ伺

¼ºÀå ÃËÁø¿äÀΰú ÀúÇØ¿äÀÎ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ÃËÁø¿äÀÎ ÇØ¼³
  • ½ÃÀå ¼ºÀå ÀúÇØ¿äÀÎ
  • ¼ºÀå ÀúÇØ¿äÀÎ ÇØ¼³

¿¹Ãø°ú µ¿Çâ

  • ½ÃÀå ¿£Áö´Ï¾î¸µ ÃøÁ¤
  • ¿¹Ãø °¡Á¤
  • ¸ÅÃâ ¿¹Ãø
  • ¸ÅÃâ ¿¹Ãø ³íÀÇ
  • Áö¿ªº° ¸ÅÃâ ¿¹Ãø
  • Áö¿ªº° ¸ÅÃâ ³»¿ª
  • Áö¿ªº° ¸ÅÃâ ¿¹Ãø ³íÀÇ
  • ±â´Éº° ¸ÅÃâ ¿¹Ãø
  • ±â´Éº° ¸ÅÃâ ¿¹Ãø ³íÀÇ
  • °áÇÕÁ¦¿Í Áõ·®Á¦ - Á¦Ç° Á¾·ùº° ¸ÅÃâ
  • °áÇÕÁ¦¿Í Áõ·®Á¦ - Á¦Ç° Á¾·ùº° ¸ÅÃâ ³íÀÇ
  • ÄÚÆÃ - Á¦Ç° Á¾·ùº° ¸ÅÃâ
  • ÄÚÆÃ - Á¦Ç° Á¾·ùº° ¸ÅÃâ ³íÀÇ
  • ºØ±«Á¦ - Á¦Ç° Á¾·ùº° ¸ÅÃâ
  • ±âŸ Á¦Ç° Á¾·ùº° ¸ÅÃâ
  • ±âŸ Á¦Ç° Á¾·ùº° ¸ÅÃâ ³íÀÇ
  • ¹ë·ùüÀÎ
  • ¹ë·ùüÀÎ ¼³¸í

°æÀï »óȲ

  • °æÀï »óȲ
  • °æÀï ȯ°æ
  • ½ÃÀå Á¡À¯À² ºÐ¼® - ÁøÃâ ±â¾÷ÀÇ È°µ¿

¼ºÀå ±âȸ¿Í Á¦¾È

  • ¼ºÀå ±âȸ1 - ¿ëÇØ¼ºÀ» ³ôÀÌ´Â ºÎÇüÁ¦ ¼ö¿ä È®´ë
  • ¼ºÀå ±âȸ2 - ºÎÇüÁ¦ Àü¹® ½ÂÀÎ ±ÔÁ¦ ±â°üÀÇ Çʿ伺
  • ¼º°ø°ú ¼ºÀåÀ» À§ÇÑ Àü·«Àû ¿øÄ¢

½ÃÀå µ¿Çâ

  • ½ÃÀå µ¿Çâ
  • »õ·Î¿î ºÎÇüÁ¦ ¼ö¿ä È®´ë
  • »õ·Î¿î ºÎÇüÁ¦ »ç·Ê
  • »õ·Î¿î ºÎÇüÁ¦ Á¾·ù 1 - ½Å±Ô ºÎÇüÁ¦
  • »õ·Î¿î ºÎÇüÁ¦ Á¾·ù 2 - º¯¼º ºÎÇüÁ¦
  • »õ·Î¿î ºÎÇüÁ¦ Á¾·ù 3 - ÄÚÇÁ·Î¼¼½º ÷°¡Á¦
  • ÄÚÇÁ·Î¼¼½º ÷°¡Á¦ »ç·Ê
  • CDMO¿Í ¾Æ¿ô¼Ò½Ì
  • Á¶Á¤µÈ Á¦Çü
  • ¿¬¼º °æ±¸ °íÇüÁ¦Á¦

ºÏ¹Ì ½ÃÀå ºÐ¼®

  • ½ÃÀå ¿£Áö´Ï¾î¸µ ÃøÁ¤
  • ¸ÅÃâ ¿¹Ãø
  • ¸ÅÃâ ¿¹Ãø ³íÀÇ
  • ±â´Éº° ¸ÅÃâ ¿¹Ãø
  • ±â´Éº° ¸ÅÃâ ¿¹Ãø ³íÀÇ

À¯·´ ½ÃÀå ºÐ¼®

  • ½ÃÀå ¿£Áö´Ï¾î¸µ ÃøÁ¤
  • ¸ÅÃâ ¿¹Ãø
  • ¸ÅÃâ ¿¹Ãø ³íÀÇ
  • ±â´Éº° ¸ÅÃâ ¿¹Ãø
  • ±â´Éº° ¸ÅÃâ ¿¹Ãø ³íÀÇ

¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå ºÐ¼®

  • ½ÃÀå ¿£Áö´Ï¾î¸µ ÃøÁ¤
  • ¸ÅÃâ ¿¹Ãø
  • ¸ÅÃâ ¿¹Ãø ³íÀÇ
  • ±â´Éº° ¸ÅÃâ ¿¹Ãø
  • ±â´Éº° ¸ÅÃâ ¿¹Ãø ³íÀÇ

±âŸ Áö¿ª ½ÃÀå ºÐ¼®

  • ½ÃÀå ¿£Áö´Ï¾î¸µ ÃøÁ¤
  • ¸ÅÃâ ¿¹Ãø
  • ¸ÅÃâ ¿¹Ãø ³íÀÇ
  • ±â´Éº° ¸ÅÃâ ¿¹Ãø
  • ±â´Éº° ¸ÅÃâ ¿¹Ãø ³íÀÇ

°á·Ð

  • °á·Ð : 3´ë ¿¹Ãø
  • ¸éÃ¥»çÇ×

ºÎ·Ï

  • ½ÃÀå ¿£Áö´Ï¾î¸µ Á¶»ç ¹æ¹ý
  • µµÇ¥
KSM 20.07.09

Flexible Oral Solid Dosage Forms Along with Patient-compliant Formulations will Drive Market Growth

Excipients have been a part of the pharmaceutical industry and their demand is expected to increase during the forecast period. This is owing to their ability to perform various functions such as improving the stability of the active pharmaceutical ingredient (API), modifying drug release, and masking taste. Expanding patient base coupled with the need to develop cost-effective drugs has led to the growth of generics. This has simultaneously driven the need of excipients that can be successfully utilized for these drugs. Excipients impart no medicinal properties to the drug; they have well-defined roles ranging from protecting the API to easing the manufacturing process. Factors such as patent expiration of blockbuster drugs, which will consequently boost the demand for generic drugs, and increasing demand for patient-compliant drugs have boosted the demand for oral solid dosage excipients. However, a stringent regulatory process is one of the roadblocks to the development of novel excipients. Long development timelines, high investment into R&D, and chances of failure have prevented manufacturers from developing novel excipients. For instance, antioxidants such as ascorbic acid are used in combination with compounds that are prone to oxidation, hence improving the efficiency of the formulation.

Areas of Growth:

Continuous manufacturing technology has gained prominence in the solid drug manufacturing arena. Although traditional processes are still incorporated in the continuous process line, the requirement of ingredients has differed. Therefore, there is a need for excipients that are well suited for the continuous process. The rise in the geriatric, children and mentally-disabled population has increased the demand for flexible oral dosage formulations including chewable tablets and lozenges. With the influx of such flexible oral solid dosage formations, the demand for excipients compatible with them has subsequently increased.

Regional Analysis:

North America has dominated the market and is expected to sustain this position during the forecast period. Strong economic growth increases the affordability quotient, which results in an increased demand for better healthcare services in the region. Asia-Pacific (APAC), on the other hand, is expected to witness the highest growth during the period of this study.

Competitive Structure:

In terms of market participation, Tier 1 companies including BASF, Ashland, Evonik, and Roquette occupied a share of around 45%-55% thus dominating the market. Tier 2 companies held a share of 25%-35%, followed by Tier 3 companies with a share of 10%-15%. Moreover, Tier 1 and Tier 2 companies have adopted strategies like partnerships and acquisitions to expand their customer base and establish a global presence.

Table of Contents

Executive Summary

  • Executive Summary-Strategic Factsheet
  • Market Engineering Measurements
  • CEO's Perspective

Market Overview

  • Market Definitions
  • Market Segmentation
  • Geographic Scope
  • Key Questions this Study will Answer
  • Percent Revenue Forecast by Region
  • Market Segmentation Description

Regulatory Guidelines

  • Excipients and Compendia Monograph
  • Good Manufacturing Practice (GMP) Guide Timeline
  • The Need for Certification

Drivers and Restraints-Total Oral Solid Dosage Excipients Market

  • Market Drivers
  • Drivers Explained
  • Drivers Explained (continued)
  • Drivers Explained (continued)
  • Market Restraints
  • Restraints Explained
  • Restraints Explained (continued)

Forecasts and Trends-Total Oral Solid Dosage Excipients Market

  • Market Engineering Measurements
  • Forecast Assumptions
  • Revenue Forecast
  • Revenue Forecast Discussion
  • Percent Revenue Forecast by Region
  • Revenue Forecast by Region
  • Revenue Breakdown by Region
  • Revenue Forecast Discussion by Region
  • Revenue Forecast Discussion by Region (continued)
  • Percent Revenue Forecast by Functionality
  • Revenue Forecast by Functionality
  • Revenue Forecast Discussion by Functionality
  • Binders & Fillers Segment-Percent Revenue by Product Type
  • Binders & Fillers Segment-Percent Revenue Discussion by Product Type
  • Coatings Segment-Percent Revenue by Product Type
  • Coatings Segment-Percent Revenue Discussion by Product Type
  • Disintegrants Segment-Percent Revenue by Product Type
  • Others Segment-Percent Revenue by Product Type
  • Others Segment-Percent Revenue Discussion by Product Type
  • Total Oral Solid Dosage Excipients Market Value Chain
  • Value Chain Description

Competitive Landscape-Total Oral Solid Dosage Excipients Market

  • Oral Solid Dosage Excipients Market-Competitive Landscape
  • Competitive Environment
  • Market Share Analysis-Market Participant Activities
  • Market Share Analysis-Market Participant Activities (continued)

Growth Opportunities and Companies to Action

  • Growth Opportunity 1-Increasing Demand for Solubility-enhancing Excipients
  • Growth Opportunity 2-Need for an Exclusive Excipient Approval Regulatory Agency
  • Strategic Imperatives for Success and Growth

Trends in the Total Oral Solid Dosage Excipients Market

  • Market Trends
  • Increasing Demand for New Excipients
  • Examples of New Excipients
  • Examples of New Excipients (continued)
  • Types of New Excipients 1-Novel Excipients
  • Types of New Excipients 2-Modified Excipients
  • Types of New Excipients 3-Co-processed Excipients
  • Examples of Co-processed Excipients
  • CDMO & Outsourcing
  • Modified Dosage Forms
  • Flexible Oral Solid Dosage Forms

North America Analysis

  • Market Engineering Measurements
  • Revenue Forecast
  • Revenue Forecast Discussion
  • Percent Revenue Forecast by Functionality
  • Revenue Forecast by Functionality
  • Revenue Forecast Discussion by Functionality

Europe Analysis

  • Market Engineering Measurements
  • Revenue Forecast
  • Revenue Forecast Discussion
  • Percent Revenue Forecast by Functionality
  • Revenue Forecast by Functionality
  • Revenue Forecast Discussion by Functionality

APAC Analysis

  • Market Engineering Measurements
  • Revenue Forecast
  • Revenue Forecast Discussion
  • Percent Revenue Forecast by Functionality
  • Revenue Forecast by Functionality
  • Revenue Forecast Discussion by Functionality

Rest of World (RoW) Analysis

  • Market Engineering Measurements
  • Revenue Forecast
  • Revenue Forecast Discussion
  • Percent Revenue Forecast by Functionality
  • Revenue Forecast by Functionality
  • Revenue Forecast Discussion by Functionality

The Last Word

  • The Last Word-3 Big Predictions
  • Legal Disclaimer

Appendix

  • Market Engineering Methodology
  • List of Exhibits
  • List of Exhibits (continued)
  • List of Exhibits (continued)
  • List of Exhibits (continued)
Back to Top
ÀüÈ­ ¹®ÀÇ
F A Q